A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

Despite attractive valuation metrics, the uncertainty surrounding Merck's future drug portfolio and revenue generation makes it a less favorable buy at this time. MRK stock's annual dividend yield ...

(Bloomberg) -- Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for ...

In addition, Merck will pay up to $1.77 billion in milestone payments as well as royalties on the drug’s future sales to Hengrui Pharma. The deal is expected to be closed in the second quarter ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

March 25 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals (600276.SS), opens new tab worth up to $2 billion ...

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...

Merck will partner with Chinese biotech Abbisko Therapeutics to market and sell the bone-tumor treatment pimicotinib globally, expanding its commercialization rights for the drug beyond Asia. The ...

pending the drug’s approval. With a strong P/E ratio of 13.6 and consistent dividend payments for 55 consecutive years, InvestingPro data reveals Merck’s solid financial foundation for such ...